Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Senores Pharmaceuticals IPO is a book build issue of ₹582.11 crores. The issue is a combination of fresh issue of 1.28 crore shares aggregating to ₹500.00 crores and offer for sale of 0.21 crore shares aggregating to ₹82.11 crores.
Senores Pharmaceuticals IPO bidding started from Dec 20, 2024 and ended on Dec 24, 2024. The allotment for Senores Pharmaceuticals IPO was finalized on Dec 26, 2024. The shares got listed on BSE, NSE on Dec 30, 2024.
Senores Pharmaceuticals IPO price band is set at ₹391.00 per share . The lot size for an application is 38. The minimum amount of investment required by an retail is ₹14,136 (38 shares). The lot size investment for sNII is 14 lots (532 shares), amounting to ₹2,08,012, and for bNII, it is 68 lots (2,584 shares), amounting to ₹10,10,344.
The issue includes a reservation of up to 75,000 shares for employees offered at a discount of ₹0.00 to the issue price.
Equirus Capital Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Senores Pharmaceuticals IPO RHP for detailed Information.
| IPO Date | December 20, 2024 to December 24, 2024 |
| Listing Date | December 30, 2024 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹372 to ₹391 per share |
| Issue Price Final | ₹391 per share |
| Lot Size | 38 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 1,48,87,723 shares (aggregating up to ₹582.11 Cr) |
| Fresh Issue | 1,27,87,723 shares (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 21,00,000 shares of ₹10 (aggregating up to ₹82.11 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,32,65,865 shares |
| Share Holding Post Issue | 4,60,53,588 shares |
Senores Pharmaceuticals IPO offers total 1,48,87,723 shares. Out of which 1,11,09,543 (74.62%) allocated to QIB, 44,43,818 (29.85%) allocated to QIB, 22,21,908 (14.92%) allocated to NII, 14,81,272 (9.95%) allocated to RII and 66,65,725 (44.77%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 1,11,09,543 (74.62%) | NA |
| − Anchor Investor Shares Offered | 66,65,725 (44.77%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 44,43,818 (29.85%) | NA |
| NII (HNI) Shares Offered | 22,21,908 (14.92%) | NA |
| − bNII > ₹10L | 14,81,272 (9.95%) | 2,784 |
| − sNII < ₹10L | 7,40,636 (4.97%) | 1,392 |
| Retail Shares Offered | 14,81,272 (9.95%) | 38,980 |
| Employee Shares Offered | 75,000 (0.50%) | NA |
| Total Shares Offered | 1,48,87,723 (100.00%) |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Up to Rs 2 Lakhs | Yes |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Senores Pharmaceuticals IPO raises ₹260.63 crore from anchor investors. Senores Pharmaceuticals IPO Anchor bid date is December 19, 2024. Senores Pharmaceuticals IPO Anchor Investors list
| Bid Date | December 19, 2024 |
| Shares Offered | 66,65,725 |
| Anchor Portion Size (In Cr.) | 260.63 |
| Anchor lock-in period end date for 50% shares (30 Days) | January 24, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | March 25, 2025 |
Senores Pharmaceuticals IPO opens on December 20, 2024, and closes on December 24, 2024.
| IPO Open Date | Fri, Dec 20, 2024 |
| IPO Close Date | Tue, Dec 24, 2024 |
| Tentative Allotment | Thu, Dec 26, 2024 |
| Initiation of Refunds | Fri, Dec 27, 2024 |
| Credit of Shares to Demat | Fri, Dec 27, 2024 |
| Tentative Listing Date | Mon, Dec 30, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on Tue, Dec 24, 2024 |
Investors can bid for a minimum of 38 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| S-HNI (Max) | 67 | 2,546 | ₹9,95,486 |
| B-HNI (Min) | 68 | 2,584 | ₹10,10,344 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.
The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.
The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.
The company's manufacturing unit is situated in Ahmedabad, Gujrat.
Competitive Strength
Senores Pharmaceuticals Limited's revenue increased by 457% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| Net Worth | 319.06 | 231.71 | 45.5 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
| Amount in ₹ Crore | ||||
The market capitalization of Senores Pharmaceuticals IPO is ₹1350.70 Cr.
KPI as of Sun, Mar 31, 2024.
| KPI | Values |
|---|---|
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt/Equity | 1.07 |
| RoNW | 23.60% |
| PAT Margin | 15.25% |
| Price to Book Value | 5.84 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 9.83 | 13.86 |
| P/E (x) | 39.77 | 28.21 |
The Company proposes to utilise the Net Proceeds towards funding the following objects:
[Dilip Davda] The company is focusing on pharma business for global markets through its global research and marketing skills. The company marked growth in its top and bottom lines for reported periods. It holds good long term relations with marquee clients. The sudden boost in its top and bottom lines from FY24 onwards raise eyebrows. Based on its recent financial performances, the issue appears aggressively priced. Well-informed investors may park funds for long term. Read detail review...
| Listing Date | December 30, 2024 |
| BSE Script Code | 544319 |
| NSE Symbol | SENORES |
| ISIN | INE0RB801010 |
| Final Issue Price | ₹391 per share |
| NSE Listing Group | EQ (Rolling) |
| BSE Listing Group | B |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹391.00 |
| Open | ₹593.70 |
| Low | ₹538.85 |
| High | ₹609.00 |
| Last Trade | ₹557.80 |
Senores Pharmaceuticals Ltd.
1101 to 1103, 11th floor,
South Tower, ONE 42 oppositeJayantilal Park,
Ambali Bopal Road, Ahmedabad,-380054
Ahmedabad, Gujarat
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: https://senorespharma.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Senores Pharmaceuticals IPO is a main-board IPO of 1,48,87,723 equity shares of the face value of ₹10 aggregating up to ₹582.11 Crores. The issue is priced at ₹391 per share. The minimum order quantity is 38.
The IPO opens on December 20, 2024, and closes on December 24, 2024.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Senores Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Senores Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Senores Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Senores Pharmaceuticals IPO opens on December 20, 2024 and closes on December 24, 2024.
Senores Pharmaceuticals IPO lot size is 38, and the minimum amount required for application is ₹14,858.
You can apply in Senores Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Senores Pharmaceuticals IPO will be done on Thursday, December 26, 2024, and the allotted shares will be credited to your demat account by Friday, December 27, 2024. Check the Senores Pharmaceuticals IPO allotment status.
The Senores Pharmaceuticals IPO listing date is on Monday, December 30, 2024.
Useful Articles
RHP